Analyst Rating Update on Pacific Biosciences of California (PACB)

Pacific Biosciences of California (NASDAQ:PACB) has an average broker rating of 1.6, which is interpreted as a Buy, as rated by 5 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 4, which is also a Sell.

Pacific Biosciences of California (NASDAQ:PACB) stock is expected to deviate a maximum of $3.7 from the average target price of $11.8 for the short term period. 5 Street Experts have initiated coverage on the stock with the most promising target being $18 and the most muted being $8.

For the current week, the company shares have a recommendation consensus of Buy. Also, MKM Partners initiates coverage on Pacific Biosciences of California (NASDAQ:PACB) The current rating of the shares is Neutral. Equity Analysts at the Firm announces the price target to $16.5 per share. The rating by the firm was issued on April 15, 2016.

Pacific Biosciences of California (NASDAQ:PACB): On Tuesdays trading session , Opening price of the stock was $7.98 with an intraday high of $8.16. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $7.41. However, the stock managed to close at $7.57, a loss of 2.45% for the day. On the previous day, the stock had closed at $7.76. The total traded volume of the day was 1,940,749 shares.

In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (SVP, Research & Development) of Pacific Biosciences Of California, Inc., Phillips James Michael had sold 20,000 shares worth of $205,800 in a transaction dated April 25, 2016. In this transaction, 20,000 shares were sold at $10.29 per share.

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.